Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuroblastoma breakpoint family member 26 (NBPF26)
- Target
- NBPF26
- Molecular classification
- Other, NBPF family protein, domain-rich repetitive protein, Olduvai/DUF1220 domain protein, cytoplasmic protein, not an enzyme, not a classical receptor or ion channel
01
Overview
NBPF26 is a protein rich in Olduvai domains (formerly called DUF1220), structural protein motifs that have greatly expanded in number in humans and are thought to contribute to the rapid expansion of the neocortex. The protein includes five EGF-like domains and one calcium-binding EGF-like domain, and is predicted to be located in the cytoplasm. NBPF26 interacts with other proteins including Estrogen receptor 1 (ESR1), APEX nuclease, lysine-specific demethylase 1A (KDM1A), trans-Golgi network protein 2 (TGOLN2), and tripartite motif containing 25 (TRIM25). NBPF26 is not a classical drug target and is studied primarily in the context of cancer genetics, human/primate evolution, and protein domain biology. There are no drugs known to interact directly with NBPF26, nor is it considered a biomarker or safety concern in clinical medicine at present.
- Other names
- NBPF26NBPF member 26NBPF family member NBPF26neuroblastoma breakpoint family member 26notch 2 N-terminal like R (NOTCH2NLR)
02
Biological functions
Nervous system developmentprotein domain expansion in primate evolutionpossible protein-protein interactions (predicted)
03
Disease associations
Cancer (including neuroblastoma, by association with other NBPF family members)possibly cognitive/neurodevelopmental disorders (by analogy to NBPF family and Olduvai domain copy number variation)
Beyond the preview
Go deeper on Neuroblastoma breakpoint family member 26 (NBPF26).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuroblastoma breakpoint family member 26 (NBPF26).